The initial success of Sildenafil undeniably revolutionized the drug landscape, but placing funds in companies primarily reliant on generic versions presents a complex picture. While early profits were impressive, the end of patents and the emergence of discounted alternatives have weakened the customer base. Thus, a thorough assessment of present